Nuvectis Pharma, Inc.
NVCT
$8.76
-$0.04-0.46%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.60% | 31.17% | 75.41% | 8.76% | -24.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.11% | 78.80% | 42.04% | 26.66% | 9.94% |
| Operating Income | -18.11% | -78.80% | -42.04% | -26.66% | -9.94% |
| Income Before Tax | -17.06% | -79.68% | -43.04% | -27.84% | 5.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.06% | -79.68% | -43.04% | -27.84% | 5.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.06% | -79.68% | -43.04% | -27.84% | 5.65% |
| EBIT | -18.11% | -78.80% | -42.04% | -26.66% | -9.94% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 10.38% | -80.66% | -13.13% | -6.15% | 13.92% |
| Normalized Basic EPS | 10.37% | -36.32% | -13.13% | -6.16% | -1.38% |
| EPS Diluted | 10.38% | -80.66% | -13.13% | -6.15% | 13.92% |
| Normalized Diluted EPS | 10.37% | -36.32% | -13.13% | -6.16% | -1.38% |
| Average Basic Shares Outstanding | 30.63% | 31.85% | 26.42% | 20.40% | 9.61% |
| Average Diluted Shares Outstanding | 30.63% | 31.85% | 26.42% | 20.40% | 9.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |